Bal Pharma: 7 Stock Signals Investors Are Watching Right Now
- September 22, 2026
- Posted by: Kunal Singla
- Category: Market
Bal Pharma CMP Rs 102.04. 52W range Rs 59.69 to Rs 124.68. Mcap Rs 162 crore. PE 21.39.
Quick Answer
Bal Pharma stock signals right now span an earnings picture, an FII holding of 0.20 percent, and a technical setup where the stock trades within its 52 week range of Rs 59.69 to Rs 124.68. Debt to equity stands at 1.48, and valuation sits at a P/E of 21.39. Corporate developments in the a manufacturer of pharmaceutical formulations for domestic and international markets, a member of the Micro Labs Group space add further context investors are tracking alongside these numbers. None of the seven signals here amounts to a buy or sell call on its own.
Bal Pharma stock signals are unusually layered right now, with the company trading at Rs 102.04, the stock trades 18.2 percent below its 52 week high of Rs 124.68 and 71.0 percent above its 52 week low of Rs 59.69. Bal Pharma is a well tracked name in the a manufacturer of pharmaceutical formulations for domestic and international markets, a member of the Micro Labs Group space, and no single headline captures where the stock stands today.
This article does not make a buy, hold or sell call on Bal Pharma. It lays out seven signals investors commonly watch, each sourced from the company’s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.
Click Here to Get Free Investment Predictions
Bal Pharma Stock at a Glance
Before going through each of the seven Bal Pharma stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.
| Metric | Value |
| Bal Pharma CMP | Rs 102.04 (18 September 2026) |
| 52-Week High | Rs 124.68 |
| 52-Week Low | Rs 59.69 |
| Market Capitalisation | Rs 162 crore |
| P/E Ratio | 21.39 |
| P/B Ratio | 1.56 |
| Debt to Equity | 1.48 |
| Return on Equity | 6.49 percent |
1. Earnings Trend at Bal Pharma
Bal Pharma has delivered a one year share price return of over 20 percent, with the pharmaceutical formulations manufacturer’s return on capital employed at 8.80 percent on a trailing twelve month basis.
This is the first of the seven Bal Pharma stock signals worth tracking closely into the next results.
2. FII Holding in Bal Pharma
Bal Pharma’s FII holding stood at 0.20 percent as of 28 August 2026. DII holding stood at 0.00 percent over the same period.
This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.
3. Promoter Holding in Bal Pharma
Promoter holding in Bal Pharma stood at 50.90 percent as of 28 August 2026, one of the shareholding signals worth tracking alongside institutional flows.
This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.
4. Debt Position at Bal Pharma
Bal Pharma carries a long term debt to equity ratio of 1.48, a level worth watching for a pharmaceutical formulations manufacturer serving domestic and export markets.
This is one of the balance sheet signals worth tracking alongside the earnings trend from Signal 1, since capital raising plans can shift the picture from one quarter to the next.
5. Valuation of Bal Pharma Shares
At a P/E ratio of 21.39, Bal Pharma’s valuation reflects the market’s assessment of its position in the generic pharmaceutical formulations segment.
Whether that valuation looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.
6. Technical Trend on the Bal Pharma Chart
The sixth of these Bal Pharma stock signals is the price chart itself. The stock trades 18.2 percent below its 52 week high of Rs 124.68 and 71.0 percent above its 52 week low of Rs 59.69.
Over the past year the stock has moved between Rs 59.69 and Rs 124.68, a range worth watching for a break in either direction as the next signal on where sentiment is heading.
7. Corporate Developments at Bal Pharma
The seventh and final of these Bal Pharma stock signals is corporate activity. Bal Pharma, a member of the Micro Labs Group incorporated in May 1987 and headquartered in Bangalore, manufactures pharmaceutical formulations including paracetamol, alprazolam, gliclazide and rifampicin for domestic and international markets.
Check the Univest Screener for live fundamentals
What These Bal Pharma Stock Signals Mean Together
None of these seven signals on its own settles the debate on Bal Pharma. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.
Investors weighing Bal Pharma would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in institutional positioning. Reading these Bal Pharma stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.
Conclusion
Bal Pharma currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Bal Pharma shares, and readers should form their own view based on their own research and risk appetite.
Download the Univest iOS App or Univest Android App to track Bal Pharma live price and more such signal based stock research.
Disclaimer: Data and figures in this article are sourced from publicly available information and the company’s exchange filings. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Bal Pharma Stock Signals
Why is Bal Pharma share price where it is right now?
Ans. Bal Pharma shares are trading The stock trades 18.2 percent below its 52 week high of Rs 124.68 and 71.0 percent above its 52 week low of Rs 59.69 shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.
What is Bal Pharma’s current FII holding?
Ans. FII holding in Bal Pharma stood at 0.20 percent as of 28 August 2026.
Is Bal Pharma’s debt position a concern right now?
Ans. Bal Pharma carries a long term debt to equity ratio of 1.48, a level worth watching for a pharmaceutical formulations manufacturer serving domestic and export markets.
What is the promoter holding in Bal Pharma?
Ans. Promoter holding in Bal Pharma stood at 50.90 percent as of 28 August 2026.
Is Bal Pharma expensive compared to its sector?
Ans. At a P/E ratio of 21.39, Bal Pharma’s valuation reflects the market’s assessment of its position in the generic pharmaceutical formulations segment.
What recent corporate developments are relevant to Bal Pharma?
Ans. Bal Pharma, a member of the Micro Labs Group incorporated in May 1987 and headquartered in Bangalore, manufactures pharmaceutical formulations including paracetamol, alprazolam, gliclazide and rifampicin for domestic and international markets.
What do the technical charts suggest about Bal Pharma right now?
Ans. The stock trades 18.2 percent below its 52 week high of Rs 124.68 and 71.0 percent above its 52 week low of Rs 59.69.
Should investors buy Bal Pharma shares at current levels?
Ans. This article does not offer a buy, hold or sell recommendation. It lays out seven Bal Pharma stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.
